REPL Stock Rises on FDA's Priority Review for Melanoma Drug BLA

Replimune Group, Inc. (REPL) announced that the FDA has accepted the biologics license application (BLA) for its lead pipeline candidate, RP1 (vusolimogene oderparepvec), in combination with Bristol Myers’ (BMY) Opdivo (nivolumab) to treat adult patients with advanced melanoma.With the FDA granting a priority review to the BLA, a decision from the regulatory body is expected on July 22, 2025.Shares of REPL were up 16.9% on Jan. 21 following the announcement of the news.The FDA also informed REPL that the ag ...